The Journal of Clinical Investigation | November 2003 | Volume 112 | Number 10

Therapeutic CD154 antibody for lupus: promise for the future?

Garnett Kelsoe

Department of Immunology, Duke University, Durham, North Carolina, USA

Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease characterized by the production of pathogenic autoantibodies. A new study (see the related article beginning on page 1506) demonstrates that passive antibody specific for the TNF family member, CD154, ameliorates disease by reducing levels of self-reactive antibody in the serum. This study demonstrates a substantial potential for anti-CD154 antibody in the treatment of humoral autoimmunity.


The autoimmune disease systemic lupus erythematosus (SLE) is characterized by the production of high-affinity IgG antibodies against double-stranded DNA (dsDNA). Typically, these pathogenic autoantibodies are encoded by mutated Ig genes, and the frequency and pattern of mutations strongly suggest that the source of autoreactive antibodies is B cells that have participated in the germinal center (GC) reaction. Indeed, GCs appear spontaneously in many strains of lupus-prone mice (1), and extraordinary numbers of GC B cells and their progeny are present in the blood of SLE patients (2).

GCs are organized collections of antigen-activated T and B lymphocytes in secondary lymphoid tissues (3) or sites of chronic inflammation (4, 5). Although transient GC-like reactions can be elicited by thymus-independent pathways (6–8), most GC responses are thymus-dependent. GC B cells require ongoing survival and proliferation signals that depend on CD154–CD40 signaling (9). CD154, a member of the TNF family, is inductively expressed on the surface of CD4 T lymphocytes, whereas its ligand, CD40, is constitutively present on B lymphocytes (reviewed in ref. 10).

T cell–dependent GCs begin with the separate activation of T and B cells by antigen (11). In secondary lymphoid tissues, binding of antigen modifies B cell chemotaxis, resulting in migration toward the T cell zone (12), where cognate T cell–B cell interaction expands both lymphocyte populations. Soon afterward, activated T and B cells emigrate from T cell areas into the reticula of follicular dendritic cells (FDCs) that define the B cell follicle (Figure 1). The immigrant B lymphocytes proliferate in the FDC reticulum to generate nascent GCs and, in the process, acquire distinctive phenotypes, including expression of the CD69 activation antigen and several differentiation markers, including CD38 and CD27. Remarkably, human CD38+ GC B cells can also express variable levels of CD154, especially under conditions of chronic stimulation (13, 14), and appear to have the capacity for continued self-activation.

GCs become polarized into histologic dark and light zones (DZ, LZ). The DZ is proximal to the T cell area and contains rapidly dividing B cells called centroblasts that express little or no surface immunoglobulin. The more distal LZ contains the bulk of the activated FDC network, antigen-specific CD4 T cells, and nondividing B cells known as centrocytes. Centrocytes express surface immunoglobulin and are thought to be the progeny of DZ centroblasts. In turn, selected centrocytes likely reenter the DZ and regain the centroblast form.

The enzyme AID (activation-induced cytidine deaminase) drives both somatic hypermutation (SHM) and immunoglobulin class switch recombination (CSR) in GC B cells (15). SHM introduces point mutations and occasional small deletions into the
V(D)J regions of transcriptionally active immunoglobulin genes. Mutations are probably introduced in centroblasts and accumulate during repeated rounds of centroblast/centrocyte migration between the DZs and LZs (Figure 1). Intense selection for higher-affinity mutants establishes GCs as foci of rapid somatic evolution and antibody affinity maturation. CSR ensures that mutated, high-affinity antibodies acquire various effector activities and can be delivered throughout the body.

With time, centrocytes leave GCs and enter into at least two phenotypically distinct compartments of memory cells (Figure 1). One compartment, comprising antigen-specific, small, resting B lymphocytes, defines the classical memory B lymphocyte. The other contains long-lived plasma cells that secrete high-affinity antibody and are capable of maintaining significant levels of serum antibody for years, if not decades. Characteristically, fully differentiated human plasma cells express high levels of CD38.

Potential cell targets for anti-CD154

There are at least three stages of humoral immune responses in which interruption of CD154-CD40 signaling can abrogate the GC reaction and antibody responses (Figure 1). Anti-CD154 can (i) interrupt the initial, cognate interaction between antigen-specific T and B lymphocytes at the interface of T and B cell zones (follicles) in secondary lymphoid tissues (I). CD40-CD154 interaction results in the local proliferation of both lymphocyte types. Following clonal expansion, a fraction of activated T and B cells, prompted by CD40-CD154 signaling, migrate into the follicle to initiate the GC reaction (II). In GCs, B cells proliferate and activate AID-dependent SHM and CSR. Other clonally related B lymphocytes are retained in extra-follicular sites and differentiate into antibody-forming cells (AFCs), or plasma cells (III). These transient AFCs do not express AID and do not support CSR and SHM. In GCs, centroblasts proliferate in the DZ, migrate to the LZ as centrocytes, present antigen to LZ T cells, and receive signals that direct either their exit from the GC or return to the DZ (IV). Centrocytes that do not receive survival signals die by apoptosis. Active GCs require continuous CD40-CD154 signaling; these signals may represent homotypic interaction between CD40+CD154+ centroblasts or heterotypic signals between CD40+ centrocytes and CD154+CD4 T cells. Selected B cells exit the GC (V) to enter the memory or long-lived plasma cell compartments. Grammer et al. (17) observe that passive anti-CD154 reduces the numbers of IgD+CD38+ GC precursors (I and II) and CD38bright plasma cells (III and V) but has little effect on circulating GC (IgD–CD38+) cells (IV). The primary effect(s) of CD154 antibody in SLE patients may be to interrupt the early initiation (I) and/or migrations steps (II) of the GC reaction.

Passive CD154 antibody therapy for lupus

In this issue of the JCI, Amrie Grammer and colleagues demonstrate that administration of a humanized monoclonal antibody specific for CD154 (16) produced significant clinical benefit in a small group of active SLE patients (17). Anti-CD154 promptly decreased levels of dsDNA serum autoantibody and also diminished the numbers of GC B cells and plasma cells circulating in the blood. While dsDNA antibody levels rebounded after treatment, other objective measures of disease including proteinuria and scores on a standardized index of SLE activity (SLEDAI) remained significantly suppressed over a 20-month post-treatment period. These promising results are tempered by the fact that this clinical study was prematurely ended due to adverse side effects (16). Nonetheless, the substantial clinical improvements observed by Grammer et al. suggest a therapeutic strategy of considerable potential. But how, and where, does anti-CD154 antibody ameliorate SLE?
specific T and B lymphocytes within and/or adjacent to the T cell areas of lymph nodes or spleen. Blockade of this interaction prevents both the formation of GCs and the initial production of plasmacytes. Later in the response, anti-CD154 disrupts GCs either by (ii) preventing homotypic CD154-CD40 interaction among proliferating DZ centroblasts; or (iii) interfering with collaboration between LZ T cells and centrocytes. Of note, Grammer et al. (17) find that anti-CD154 elicits relatively little change in the numbers of IgD+CD38+ blood cells in SLE patients but rather causes substantial reductions in the numbers of IgD-CD38+ cells and CD38high plasmacytes. Reductions in these pre-switch GC cells and plasmacytes correlate with reductions in autoantibody titers and DNA-specific blood plasmacytes (16). The biased effects on pre-switch cells and plasmacytes suggests that the primary benefit of anti-CD154 treatment in SLE may be the disruption of plasmacyte generation/differentiation, perhaps at a point before B cells become fully differentiated into centroblasts or centrocytes.

Even though passive CD154 antibody did not reduce the number of IgD-CD38+ GC cells in the blood of SLE patients, the ability to abrogate active GC responses remains an attractive feature of this therapy (17). In SLE, IgG autoantibodies against dsDNA appear to descend from B cell clones that do not react to DNA. These pathogenic autoantibodies arise by SHM, not in response to DNA but to pathogenic autoantibodies arise by clones that do not react to DNA. These active feature of this therapy (17). In SLE patients, the ability to abrogate specific T and B lymphocytes within and/or adjacent to the T cell areas of lymph nodes or spleen. Blockade of this interaction prevents both the formation of GCs and the initial production of plasmacytes. Later in the response, anti-CD154 disrupts GCs either by (ii) preventing homotypic CD154-CD40 interaction among proliferating DZ centroblasts; or (iii) interfering with collaboration between LZ T cells and centrocytes. Of note, Grammer et al. (17) find that anti-CD154 elicits relatively little change in the numbers of IgD+CD38+ blood cells in SLE patients but rather causes substantial reductions in the numbers of IgD-CD38+ cells and CD38high plasmacytes. Reductions in these pre-switch GC cells and plasmacytes correlate with reductions in autoantibody titers and DNA-specific blood plasmacytes (16). The biased effects on pre-switch cells and plasmacytes suggests that the primary benefit of anti-CD154 treatment in SLE may be the disruption of plasmacyte generation/differentiation, perhaps at a point before B cells become fully differentiated into centroblasts or centrocytes.

Even though passive CD154 antibody did not reduce the number of IgD-CD38+ GC cells in the blood of SLE patients, the ability to abrogate active GC responses remains an attractive feature of this therapy (17). In SLE, IgG autoantibodies against dsDNA appear to descend from B cell clones that do not react to DNA. These pathogenic autoantibodies arise by SHM, not in response to DNA but to pathogenic autoantibodies arise by clones that do not react to DNA. These active feature of this therapy (17). In SLE patients, the ability to abrogate specific T and B lymphocytes within and/or adjacent to the T cell areas of lymph nodes or spleen. Blockade of this interaction prevents both the formation of GCs and the initial production of plasmacytes. Later in the response, anti-CD154 disrupts GCs either by (ii) preventing homotypic CD154-CD40 interaction among proliferating DZ centroblasts; or (iii) interfering with collaboration between LZ T cells and centrocytes. Of note, Grammer et al. (17) find that anti-CD154 elicits relatively little change in the numbers of IgD+CD38+ blood cells in SLE patients but rather causes substantial reductions in the numbers of IgD-CD38+ cells and CD38high plasmacytes. Reductions in these pre-switch GC cells and plasmacytes correlate with reductions in autoantibody titers and DNA-specific blood plasmacytes (16). The biased effects on pre-switch cells and plasmacytes suggests that the primary benefit of anti-CD154 treatment in SLE may be the disruption of plasmacyte generation/differentiation, perhaps at a point before B cells become fully differentiated into centroblasts or centrocytes.